Why the study?
How do left atrial morphology, size, and function compare between patients with transthyretin cardiac amyloidosis, primary hypertrophic cardiomyopathy, and controls?
How do left atrial morphology, size, and function compare between patients with transthyretin cardiac amyloidosis, primary hypertrophic cardiomyopathy, and controls?
Left atrial reservoir and pump function are more severely impaired in transthyretin cardiac amyloidosis than in hypertrophic cardiomyopathy, independent of LA volume and LVEF, suggesting a more altered LA wall structure.
LA strain differences may aid TTR-CA differentiation from HCM; hypothesis-generating and should not yet change practice.
No takes yet. Share an insight, caveat, or question.
Gregorio et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: